Acrivon Therapeutics (ACRV) director receives 9,366 RSUs vesting in 2027

Q: How many RSUs did Palani Santhosh receive from Acrivon Therapeutics (ACRV)?

Palani Santhosh received 9,366 restricted stock units. The Form 4 states these RSUs are tied to Acrivon Therapeutics’ Common Stock, with each unit representing a contingent right to receive one share upon vesting, assuming continuous service through the vesting date.

Q: When do Palani Santhosh’s Acrivon Therapeutics (ACRV) RSUs vest?

The RSUs are scheduled to vest on May 18, 2027. The footnote explains that all 9,366 restricted stock units vest in full on that date, provided Palani Santhosh maintains continuous service with the company through the stated vesting date.

Q: What is Palani Santhosh’s reported Acrivon Therapeutics (ACRV) holding after this grant?

The filing shows 9,366 shares following the transaction. The Form 4 reports total shares following the award at 9,366, held directly, corresponding to the newly granted restricted stock units tied to Acrivon Therapeutics’ Common Stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Palani Santhosh reported acquisition or exercise transactions in this Form 4 filing.

Acrivon Therapeutics director Palani Santhosh reported an equity grant. He received 9,366 shares of Common Stock in the form of restricted stock units (RSUs), awarded as compensation rather than an open-market purchase. Each RSU represents a right to receive one share of Common Stock.

The RSUs will vest in full on May 18, 2027, if he continues to serve through that date. Following this grant, the filing shows 9,366 shares held directly, reflecting his entire reported position in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Palani Santhosh

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	9,366	$0.00	--

Holdings After Transaction: Common Stock — 9,366 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSU grant size: 9,366 RSUs Vesting date: May 18, 2027 Price per share: $0.0000 per share +2 more

5 metrics

RSU grant size 9,366 RSUs Grant to director Palani Santhosh

Vesting date May 18, 2027 RSUs vest in full on this date

Price per share $0.0000 per share Compensation-related grant, not open-market purchase

Shares following transaction 9,366 shares Direct holdings after the award

Transaction code A Grant, award, or other acquisition

Key Terms

restricted stock units ("RSUs"), contingent right, vest in full, transaction code "A"

4 terms

restricted stock units ("RSUs") financial

"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right..."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

vest in full financial

"These RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service..."

transaction code "A" financial

"transaction_code_description": "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

05/20/2026 - 04:35 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Palani Santhosh

(Last)

(First)

(Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/18/2026		A⁽¹⁾		9,366	A	$0	9,366	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Adam D. Levy, Attorney-in-Fact	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Acrivon Therapeutics (ACRV) report for Palani Santhosh?

Acrivon Therapeutics reported an equity grant to director Palani Santhosh. He received 9,366 restricted stock units, each representing one share of Common Stock, as a compensation award rather than an open-market purchase, according to the Form 4 filing and its accompanying footnote.

How many RSUs did Palani Santhosh receive from Acrivon Therapeutics (ACRV)?

Palani Santhosh received 9,366 restricted stock units. The Form 4 states these RSUs are tied to Acrivon Therapeutics’ Common Stock, with each unit representing a contingent right to receive one share upon vesting, assuming continuous service through the vesting date.

When do Palani Santhosh’s Acrivon Therapeutics (ACRV) RSUs vest?

The RSUs are scheduled to vest on May 18, 2027. The footnote explains that all 9,366 restricted stock units vest in full on that date, provided Palani Santhosh maintains continuous service with the company through the stated vesting date.

Is Palani Santhosh’s Acrivon Therapeutics (ACRV) Form 4 transaction an open-market buy?

No, the transaction reflects a grant, not an open-market buy. The Form 4 uses transaction code "A" for grant, award, or other acquisition, and the price per share is listed as $0.0000, indicating a compensation-related restricted stock unit award.

What is Palani Santhosh’s reported Acrivon Therapeutics (ACRV) holding after this grant?

The filing shows 9,366 shares following the transaction. The Form 4 reports total shares following the award at 9,366, held directly, corresponding to the newly granted restricted stock units tied to Acrivon Therapeutics’ Common Stock.